Syndax Pharmaceuticals, Inc. (SNDX) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
SNDX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SNDX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 96.0% | -158.4% | -165.6% |
| 2024 | 96.5% | -1434.4% | -1346.1% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 100.0% | 18.8% | 17.8% |
Download Data
Export SNDX earnings history in CSV or JSON format
Free sign-in required to download data
Syndax Pharmaceuticals, Inc. (SNDX) Earnings Overview
As of May 8, 2026, Syndax Pharmaceuticals, Inc. (SNDX) reported trailing twelve-month net income of -$243M, reflecting +11.8% year-over-year growth. The company earned $-3.29 per diluted share over the past four quarters, with a net profit margin of -165.6%.
Looking at the long-term picture, SNDX's historical earnings data spans multiple years. The company achieved its highest annual net income of $25M in fiscal 2021.
Syndax Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), IMVT (-$464M net income), RVMD (-$1.37B net income), SNDX has outperformed on profitability metrics. Compare SNDX vs KYMR →
SNDX Earnings vs Peers
Earnings metrics vs comparable public companies
SNDX Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$285M | +10.5% | -$273M | $-3.29 | -165.6% | -158.4% |
| 2024 | -$319M | -52.3% | -$340M | $-3.73 | -1346.1% | -1434.4% |
| 2023 | -$209M | -40.2% | -$230M | $-2.98 | - | - |
| 2022 | -$149M | -699.1% | -$152M | $-2.46 | - | - |
| 2021 | $25M | +134.1% | $26M | $0.48 | 17.8% | 18.8% |
| 2020 | -$73M | -30.6% | -$71M | $-1.77 | -4816.7% | -4708.2% |
| 2019 | -$56M | +24.3% | -$58M | $-1.84 | -3688.5% | -3792.9% |
| 2018 | -$74M | -21.6% | -$76M | $-2.92 | -4875.5% | -5001.7% |
| 2017 | -$61M | -36.7% | -$62M | $-2.90 | -2884.3% | -2939.0% |
| 2016 | -$44M | -84.4% | -$44M | $-3.04 | -3645.2% | -3587.4% |
See SNDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNDX — Frequently Asked Questions
Quick answers to the most common questions about buying SNDX stock.
Is SNDX growing earnings?
SNDX EPS stands at $-3.29, with +11.8% growth matching the 5-year CAGR of N/A. TTM net income is $-243M. Earnings trajectory remains consistent.
What are SNDX's profit margins?
Syndax Pharmaceuticals, Inc. net margin is -165.6%, with operating margin at -158.4%. Below-average margins reflect competitive or cost pressures.
How consistent are SNDX's earnings?
SNDX earnings data spans 2011-2025. The current earnings trend is +11.8% YoY. Historical data enables comparison across business cycles.